NURIX THERAPEUTICS INC (NRIX) Stock Income Statement
NASDAQ:NRIX • US67080M1036
15.6 USD
-0.13 (-0.83%)
At close: Feb 13, 2026
15.12 USD
-0.48 (-3.08%)
Pre-Market: 2/17/2026, 5:39:19 AM
| 2025 (2025-11-30) | 2024 (2024-11-30) | 2023 (2023-11-30) | 2022 (2022-11-30) | 2021 (2021-11-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | |||
| Operating Expenses | 369.65M | 267.58M | 232.05M | 222.49M | 147.64M | |||
| Research and Development | 316.90M | 221.63M | 189.15M | 184.50M | 116.43M | |||
| Selling, General, and Administrative Expenses | 52.74M | 45.94M | 42.90M | 38.00M | 31.20M | |||
| Operating Income | -285.67M | -213.03M | -155.06M | -183.87M | -117.89M | |||
| Interest Income/Expense | 21.97M | 19.73M | 11.12M | 3.51M | 820.00K | |||
| Income Before Taxes | -263.70M | -193.30M | -143.95M | -180.36M | -117.06M | |||
| Income Tax | 760.00K | 270.00K | N/A | 0.00 | 130.00K | |||
| Net Income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | |||
| EBITDA | -276.93M | -203.71M | -147.53M | -178.52M | -115.10M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | |||
| Non GAAP EPS | -3.04 | -2.89 | -2.65 | -3.73 | -2.73 | |||
| Statistics | ||||||||
| Profit Margin | -314.90% | -354.85% | -186.98% | -466.89% | -393.92% | |||
| Operating Profit Margin | -340.16% | -390.52% | -201.41% | -475.98% | -396.27% | |||
All data in USD